|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 784.90 INR | -2.03% |
|
-6.93% | -2.77% |
| Dec. 31 | Arete Securities Starts MedPlus Health Services at Buy With INR874 Price Target | MT |
| Dec. 11 | Medplus Health Services says unit received favorable order from High Court of Telangana | RE |
| Capitalization | 94.05B 1.03B 881M 816M 767M 1.43B 1.53B 9.42B 3.72B 44.72B 3.88B 3.8B 163B | P/E ratio 2026 * |
47.8x | P/E ratio 2027 * | 40.6x |
|---|---|---|---|---|---|
| Enterprise value | 87.7B 964M 821M 761M 716M 1.33B 1.43B 8.78B 3.47B 41.7B 3.61B 3.54B 152B | EV / Sales 2026 * |
1.3x | EV / Sales 2027 * | 1.14x |
| Free-Float |
58.06% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MedPlus Health Services Limited
| 1 day | -2.03% | ||
| 1 week | -6.93% | ||
| Current month | -2.77% | ||
| 1 month | -4.34% | ||
| 3 months | +2.32% | ||
| 6 months | -12.83% | ||
| Current year | -2.77% |
| 1 week | 780.1 |  | 838.7 |
| 1 month | 780.1 | | 854.9 |
| Current year | 780.1 | | 854.9 |
| 1 year | 642 | | 1,045.3 |
| 3 years | 597.7 | | 1,045.3 |
| 5 years | 548.25 | | 1,343 |
| 10 years | 548.25 | | 1,343 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 2005-12-31 | |
| Director of Finance/CFO | - | 2022-11-10 | |
| Compliance Officer | - | 2023-03-29 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 58 | - | |
| Director/Board Member | - | - | |
| Director/Board Member | 48 | 2021-02-05 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.03% | -6.93% | +3.62% | +25.53% | 1.05B | |
| +0.30% | -0.89% | +125.30% | -2.48% | 27.41B | |
| +3.03% | +4.13% | +101.48% | -7.60% | 13.7B | |
| -1.10% | -2.27% | +13.40% | +19.07% | 6.52B | |
| +0.03% | +1.43% | -5.50% | +28.98% | 5.04B | |
| -0.40% | -1.16% | -6.34% | -36.62% | 3.88B | |
| +0.77% | +5.67% | +42.61% | -40.62% | 3.18B | |
| +0.93% | -1.87% | -22.43% | -48.02% | 3.16B | |
| Average | +0.19% | -0.80% | +31.52% | -7.72% | 7.99B | |
| Weighted average by Cap. | +0.69% | -1.53% | +77.07% | -4.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 67.63B 743M 633M 587M 552M 1.03B 1.1B 6.77B 2.68B 32.16B 2.79B 2.73B 117B | 75.48B 829M 707M 655M 616M 1.15B 1.23B 7.56B 2.99B 35.89B 3.11B 3.05B 131B |
| Net income | 1.96B 21.58M 18.39M 17.04M 16.03M 29.83M 32M 197M 77.72M 934M 80.93M 79.27M 3.41B | 2.31B 25.38M 21.63M 20.04M 18.85M 35.09M 37.63M 231M 91.4M 1.1B 95.17M 93.22M 4.01B |
| Net Debt | -6.35B -69.72M -59.43M -55.06M -51.78M -96.39M -103M -636M -251M -3.02B -261M -256M -11.01B | -8.25B -90.69M -77.3M -71.62M -67.36M -125M -134M -827M -327M -3.92B -340M -333M -14.32B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-21 | 784.90 ₹ | -2.03% | 190,218 |
| 26-01-20 | 801.15 ₹ | -1.66% | 65,740 |
| 26-01-19 | 814.65 ₹ | -2.25% | 54,609 |
| 26-01-16 | 833.40 ₹ | -0.11% | 49,762 |
| 26-01-14 | 834.30 ₹ | -1.07% | 49,978 |
Delayed Quote NSE India S.E., January 21, 2026 at 06:49 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MEDPLUS Stock
Select your edition
All financial news and data tailored to specific country editions
